Home › Funds › Avoro Capital Advisors LLC › XENE
Avoro Capital Advisors LLC position in XENE
XENON PHARMACEUTICALS INC · Health Care
Avoro Capital Advisors LLC reported holding 5,500,000 shares of XENE (XENON PHARMACEUTICALS INC) in its Q3 2026 13F filing — a position valued at US$204.5M, representing 2.12% of its reported portfolio and ranking #12 among its reported holdings. Avoro Capital Advisors LLC has disclosed XENE holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
Last updated: 2026-11-16 · Source: SEC EDGAR Form 13F-HR
How Avoro Capital Advisors LLC's XENE position evolved
Avoro Capital Advisors LLC first disclosed a stake in XENE in Q3 2023 at 4,900,000 shares (US$167.4M). The position peaked in Q2 2026 at 5,777,777 shares, worth US$348.7M. Across 13 filings, Avoro Capital Advisors LLC increased the stake 3 time(s), trimmed it 2 time(s) and left it unchanged 7 time(s). The most recent filing (Q3 2026) shows 5,500,000 shares valued at US$204.5M — a reduction of -277,777 shares quarter over quarter..
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 4.90M | $167.38M | New |
| Q4 2023 | 5.67M | $261.01M | Add |
| Q1 2024 | 5.67M | $243.95M | Hold |
| Q2 2024 | 5.67M | $220.94M | Hold |
| Q3 2024 | 5.67M | $223.10M | Hold |
| Q4 2024 | 5.67M | $222.13M | Hold |
| Q1 2025 | 5.74M | $192.63M | Add |
| Q2 2025 | 5.40M | $169.02M | Reduce |
| Q3 2025 | 5.40M | $216.81M | Hold |
| Q4 2025 | 5.42M | $243.12M | Hold |
| Q1 2026 | 5.78M | $335.98M | Add |
| Q2 2026 | 5.78M | $348.75M | Hold |
| Q3 2026 | 5.50M | $204.54M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About XENE and 13F data
XENE (XENON PHARMACEUTICALS INC) is a Health Care company. 31 other funds we track also report a position in XENE — the largest reported positions include DRIEHAUS CAPITAL MANAGEMENT LLC (US$132.3M), DEERFIELD MANAGEMENT COMPANY, L.P. (US$97.5M), Affinity Asset Advisors, LLC (US$70.7M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding XENE
- DRIEHAUS CAPITAL MANAGEMENT LLC 3.56M sh · $132.31M · Q3 2026
- DEERFIELD MANAGEMENT COMPANY, L.P. 1.62M sh · $97.52M · Q2 2026
- Affinity Asset Advisors, LLC 1.90M sh · $70.67M · Q3 2026
- BRAIDWELL LP 1.13M sh · $68.29M · Q2 2026
- ORBIMED ADVISORS LLC 892.47K sh · $53.87M · Q2 2026
- Caligan Partners LP 889.94K sh · $53.72M · Q2 2026
- Vestal Point Capital, LP 700.00K sh · $42.25M · Q2 2026
More on Avoro Capital Advisors LLC
FAQ
How long has Avoro Capital Advisors LLC held XENE?
Avoro Capital Advisors LLC has disclosed XENE holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
What is Avoro Capital Advisors LLC's current position in XENE?
As of Q3 2026, Avoro Capital Advisors LLC holds 5.50M shares of XENE (XENON PHARMACEUTICALS INC), valued at $204.54M, representing 2.12% of its reported portfolio and ranking #12.
Has Avoro Capital Advisors LLC been buying or selling XENE?
In the latest 13F filing (Q3 2026), Avoro Capital Advisors LLC reduced its position in XENE. The position peaked in Q2 2026 at 5.78M shares.
Which other funds hold XENE?
Other major institutional holders of XENE include DRIEHAUS CAPITAL MANAGEMENT LLC, DEERFIELD MANAGEMENT COMPANY, L.P., Affinity Asset Advisors, LLC, among 31 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.